

DABUR INDIA**INR 94****Momentum continues****ACCUMULATE**

March 18, 2009

We recently met the management of Dabur India (Dabur) for understanding its business performance and future growth strategies. Key takeaways of our meeting are:

Volume growth to remain robust in FY10

Dabur had reported strong volume growth of 14% in the December quarter (one of the highest in the FMCG space). While this was an exceptionally strong performance, the company expects to achieve fairly robust volume growth in the coming quarters as well. Consumer Health Division (CHD) and international businesses are expected to grow faster than Consumer Care Division (CCD) business. The company is witnessing better growth in the rural segment compared to earlier times. Earlier, rural growth used to lag urban growth by ~200bps, which has now corrected with both growing at an equal rate according to the management. Lower rural penetration remains a growth opportunity and Dabur has tried to tap into this segment with low unit price products and special customer acquisition drives.

Modest improvement in margins likely

Dabur expects gross margins to improve by 100-200bps for FY10 owing to correction in prices of packaging material, and input materials. However, a part of this will be passed on to consumers in terms of product promotions. However, the company is unlikely to take a price cut. In terms of ASP spends, the company is likely to increase its ad budget by ~10-15% in spite of some softening in ad rates.

Retail losses to come down

Losses in Dabur's retail venture *NewU* are likely to decrease in Q4FY09 to ~INR 25 mn (from ~INR 56 mn in Q3FY09). Dabur plans to launch 15 new stores (smaller format and house more fast moving items of many brands) in FY10 and expects an overall loss of ~ INR 100-120 mn in FY10E. The company expects to break even in FY11 as a result of attainment of critical size, falling rentals, and better sourcing.

Outlook and valuations: Positive; maintain 'ACCUMULATE'

Dabur's performance has remained strong on the back of robust volume growth which has been supported by strength in CHD and international businesses. The expected lower retail losses and better margins due to correction in prices of input material bode well for the company. At CMP of INR 94, the stock is trading at P/E of 21.6x and 18.2x and EV/EBITDA of 17.6x and 14.4x our FY09E and FY10E, respectively. We expect 15.2% CAGR in earnings over FY08-11E. We maintain our 'ACCUMULATE' recommendation with positive bias on it.

Financials

Year to March	FY08	FY09E	FY10E	FY11E
Revenues (INR mn)	23,597	27,365	32,614	37,052
Rev. growth (%)	15.6	16.0	19.2	13.6
EBITDA (INR mn)	4,037	4,548	5,490	6,257
Net profit (INR mn)	3,339	3,769	4,471	5,104
Shares outstanding (mn)	864	864	864	864
Diluted EPS (INR)	3.9	4.4	5.2	5.9
EPS growth (%)	18.1	12.9	18.6	14.1
Diluted P/E (x)	24.4	21.6	18.2	16.0
EV/EBITDA (x)	19.2	17.6	14.4	12.4
ROAE (%)	62.8	54.1	49.6	44.8

Abneesh Roy

+91-22-6620 3141
 abneesh.roy@edelcap.com

Ajay Thakur

+91-22-6620 3031
 ajay.thakur@edelcap.com

Reuters : DABU.BO
 Bloomberg : DABUR IN

Market Data


52-week range (INR) : 115 / 60
 Share in issue (mn) : 865.1
 M cap (INR bn/USD mn) : 77.0 / 1,493.9
 Avg. Daily Vol. BSE/NSE ('000) : 807.5

Share Holding Pattern (%)

Promoters* : 70.7
 MFs, FIs & Banks : 13.9
 FIIs : 8.5
 Others : 7.0
 * Promoters pledged shares : 9.2
 (% of share in issue)

Relative Performance (%)

	Sensex	Stock	Stock over Sensex
1 month	(1.7)	2.1	3.8
3 months	(12.0)	12.2	24.2
12 months	(40.1)	(2.1)	38.0



Broad-based growth likely to continue; no price cuts expected

Till now, Dabur has not seen any significant signs of down trading or slowdown. This has been because it took only a moderate price hike against a sharper price hike by some other FMCG players. Dabur had effected a moderate price hike (~4.5%, primarily in hair oil) during FY09 due to inflation in some of its key input materials. The company maintains that gaining volume growth and maintaining market share remains top priority. Company is beefing its distribution in South and West India which is expected to aid in higher volume growth.

Hair oils: The rural push and on ground activities have boosted sales of *Dabur Amla*. It has not seen any decline in trend of use of hair oil (due to launch of hair gels) and believes that gels will remain a niche area and continue to remain a negligible part of users.

Shampoos: ITC has already gained ~2.5% market share in shampoos. However, Dabur's market share has not suffered due to this and has grown (from 5.1% to 6.4%). The launch of *Vatika Black Shine* has boosted performance.

Toothpaste: Dabur expects decent growth in the toothpaste segment in FY10. It has relaunched *Babool* at the price point of INR 10 and expects it to do well. However, it expects tooth powder to continue to remain flat as consumers uptrade to toothpastes.

Baby and skin care: Baby care products witnessed volumes growth of ~13% in 9mFY09 and the company expects them to grow at similar levels in FY10 as rural demand is buoyant. *Gulabari* has done well due to its positioning as a low priced product, especially in rural areas. Dabur will continue to launch new products and activate its existing products in Skin care segment.

Foods: In 9mFY09, Dabur saw a growth of modest 12% and expects to grow faster in FY10 on the back of new products and fine tuning of distribution. In the juices category, *Real* has done well. *Activ*, which is at the top end, has grown at a slower pace, primarily due to competition from lower priced players.

Health supplements: The company expects to see decent growth in this segment. It has signed up a new brand ambassador, MS Dhoni, for *Dabur Honey* and *Chyawanprash*.

New products: Dabur plans to launch a lower priced juice product to counter cheaper competition. This will be launched in Q1FY10 in the price range of INR 55-60 (compared to INR 75-85). *Dazzl* has done well and the company expects it to acquire higher scale in FY10 from the current levels of INR 50 mn. Dabur plans to introduce new products in CHD as well.

Table 1: Segment wise 9mFY09 performance

Segments	Y-o-Y growth (%)
Hair oils	19.7
Shampoos	32.2
Oral care	3.7
Health supplements	11.2
Digestives & confectionery	6.7
Baby & skin care	22.5
Home care	11.0
Foods	11.5

Source: Company, Edelweiss research

International business to maintain pace

High oil prices boosted demand in Middle East in the past year. Dabur captured this buoyancy by advertising on 'Middle East Broadcasting Channel' which has a good reach and allocated ~20% of its sales to ASP spends (compared to ~12% in the Indian business). It caters to both the local population and Indian diaspora in these countries. It expects to grow strongly in FY10 in spite of a massive slowdown in this region.

It has local manufacturing in most international regions it is present in. Dabur imports barely ~INR 700-800 mn (largely raw material for its juice business). Hence, the impact of rupee depreciation should be largely muted. However, rupee depreciation could add to the INR reported revenues from its international operations.

Fem Care acquisition to be completed by April or May

Dabur expects Fem Care acquisition to be over by April/May 2009. It will be consolidated after that in both quarterly and annual numbers. The company expects it to grow strongly and be accretive from FY11 while being neutral in FY10.

No major capital expenditure; tax rates to remain stable

Around 90% of Dabur's manufacturing is in house. It plans to set up a new factory at a capital expenditure of INR 1.5 bn (financed from internal accruals) in Baddi in FY10 which will take care of its future demand. The company currently has a low debt of INR 1.5 bn in its book. It expects tax rates to remain broadly in the range of ~13-14% over the next two years since it will continue to enjoy tax benefits from tax exempted locations.

Company Description

Dabur has three divisions in India apart from its international operations. Consumer care division (CCD) offers a wide range of products in hair care, oral care, health supplements, digestives and candies, and baby and skin care products, based on ayurveda. The consumer health division (CHD) includes over-the-counter (OTC) products, Asavs, and branded ethical, and classic products. The third division, Dabur Foods Ltd produces fruit juices, cooking pastes, sauces, and items for institutional food purchases. Dabur is unique among its FMCG peers because of its positioning as an Indian company whose products are derived from exotic sources such as ancient ayurvedic texts and natural ingredients such as herbs.

The company has various brand leaders in different market segments - Dabur Chyawanprash, a health tonic, and Hajmola - a digestive tablet. Real, launched during 1996-97, has also successfully carved its niche in the market.

Investment Theme

Dabur's broad product portfolio provides the best play on Indian FMCG spend by virtue of its strong presence in less penetrated and high growth categories. Dabur's positioning on the 'health and wellness' platform, backed by its ANH (ayurvedic/natural/herbal) image is very progressive. This, combined with its demonstrated ability to create new categories and sub-categories, makes it best-placed to capture lifestyle changes-led growth in the FMCG space. Dabur has also demonstrated its ability to make and integrate smart acquisitions (Balsara) that complement its product portfolio and thereby drive inorganic growth. Improvement in margins of foods and international businesses are expected to result in improvement in margins for the consolidated operations.

Key Risks

A slowdown in rural demand due to lower government spending or a monsoon failure could impact Dabur's revenues significantly. The company's products such as Dabur Chyawanprash and Dabur Lal Tail are prominently sold in the rural areas, and hence, depend on growth in rural demand.

Further, Ayush, the Ayurvedic Association of India, has recently declared strict adherence to ayurvedic norms; the body asked many companies to change the formulation of Chyawanprash. Any such changes in future could dampen the sales, especially during the change of formulation, when the product is taken off the shelf.

Financial Statements

Income statement		(INR mn)				
Year to March	FY07	FY08	FY09E	FY10E	FY11E	
Gross revenues	20,784	23,949	27,837	33,153	37,660	
Excise duties	371	352	472	540	608	
Net revenues	20,413	23,597	27,365	32,614	37,052	
Cost of materials	9,711	11,010	12,862	15,150	17,249	
Gross profit	10,702	12,587	14,503	17,464	19,803	
Employee costs	1,667	1,993	2,309	2,840	3,174	
Advertisement & sales costs	2,559	2,955	3,489	4,226	4,797	
Other general expenditure	3,045	3,602	4,157	4,907	5,575	
EBITDA	3,432	4,037	4,548	5,490	6,257	
Depreciation	343	364	420	504	601	
EBIT	3,090	3,672	4,128	4,986	5,656	
Other income	255	339	401	396	399	
EBIT incl. other income	3,345	4,012	4,529	5,382	6,055	
Net interest	150	167	157	174	148	
PBT	3,195	3,844	4,372	5,209	5,907	
Provision for taxation	373	507	603	737	804	
Core PAT	2,822	3,338	3,769	4,471	5,104	
Profit after tax	2,822	3,338	3,769	4,471	5,104	
Minority interest	(9)	(1)	-	-	-	
Profit after tax after minority interest	2,831	3,339	3,769	4,471	5,104	
Equity shares outstanding (mn)	863	864	864	864	864	
EPS (INR) basic	3.3	3.9	4.4	5.2	5.9	
Diluted shares (mn)	863	864	864	864	864	
EPS (INR) fully diluted	3.3	3.9	4.4	5.2	5.9	
CEPS (INR)	3.7	4.3	4.8	5.8	6.6	
DPS	1.4	1.5	1.9	2.2	2.5	
Dividend payout ratio (%)	49.3	45.4	50.5	50.5	50.5	

Common size metrics

Year to March	FY07	FY08	FY09E	FY10E	FY11E
Cost of materials	47.6	46.7	47.0	46.5	46.6
Employee costs	8.2	8.4	8.4	8.7	8.6
Advertising & sales costs	12.5	12.5	12.8	13.0	12.9
Other general expenditure	14.9	15.3	15.2	15.0	15.0
Depreciation	1.7	1.5	1.5	1.5	1.6
Net interest expenditure	0.7	0.7	0.6	0.5	0.4
EBITDA margin	16.8	17.1	16.6	16.8	16.9
EBIT margin	15.1	15.6	15.1	15.3	15.3
Net profit margin	13.8	14.1	13.8	13.7	13.8

Growth metrics

Year to March	FY07	FY08	FY09E	FY10E	FY11E
Revenues	18.5	15.6	16.0	19.2	13.6
EBITDA	19.8	17.6	12.7	20.7	14.0
PBT	24.5	20.3	13.7	19.1	13.4
Net profit	32.2	18.0	12.9	18.6	14.1
EPS	24.5	18.1	12.9	18.6	14.1

Balance sheet (INR mn)					
As on 31st March	FY07	FY08	FY09E	FY10E	FY11E
Share capital	863	864	864	864	864
Reserves	3,933	5,312	7,178	9,392	11,920
Shareholders' funds	4,796	6,176	8,042	10,257	12,784
Secured loans	1,204	976	976	976	976
Unsecured loans	395	16	16	16	16
Borrowings	1,599	992	992	992	992
Minority interests	45	48	48	48	48
Deferred tax (net)	245	33	33	33	33
Sources of funds	6,684	7,248	9,114	11,328	13,856
Gross block	6,172	7,297	10,175	11,540	12,732
Less depreciation	2,381	2,644	3,064	3,568	4,169
Net fixed assets	3,792	4,653	7,111	7,971	8,563
Investments	807	2,037	837	837	837
<i>Current assets</i>	6,405	7,739	8,056	9,886	12,325
Inventories	2,571	3,025	3,316	3,800	4,332
Sundry debtors	1,420	1,723	1,712	1,962	2,236
Cash and bank balance	607	766	803	1,899	3,531
Loans and advances	1,807	2,225	2,225	2,225	2,225
Current liabilities	4,518	7,321	7,030	7,506	8,009
Liabilities	3,615	4,580	4,289	4,765	5,268
Provisions	902	2,741	2,741	2,741	2,741
Working capital	1,887	418	1,027	2,380	4,316
Misc expenditure	198	140	140	140	140
Uses of funds	6,684	7,248	9,114	11,328	13,856
BV (INR)	5.3	7.0	9.1	11.7	14.6

Cash flow statement (INR mn)					
Year to March	FY07	FY08	FY09E	FY10E	FY11E
Net profit	2,831	3,339	3,769	4,471	5,104
Depreciation	343	364	420	504	601
Deferred tax	(14)	8	0	0	0
Others	634	(1,406)	0	(0)	(0)
Gross cash flow	3,794	2,305	4,189	4,976	5,705
Less: Changes in WC	1,440	(1,628)	571	257	304
Operating cash flow	2,354	3,933	3,617	4,719	5,401
Less: Capex	(990)	1,225	2,878	1,365	1,193
Free cash flow	3,344	2,708	739	3,353	4,208

Cash flow metric (INR mn)					
Year to March	FY07	FY08	FY09E	FY10E	FY11E
Operating cash flow	2,354	3,933	3,617	4,719	5,401
Financing cash flow	(1,472)	(1,402)	(1,910)	(2,271)	(2,603)
Investing cash flow	(787)	(2,372)	(1,670)	(1,352)	(1,166)
Net cash flow	95	159	37	1,096	1,632
Capex	990	(1,225)	(2,878)	(1,365)	(1,193)
Dividends paid	(1,768)	(665)	(1,626)	(1,929)	(2,202)
Share issuance / (buyback)	2	1	0	0	0

Ratios

Year to March	FY07	FY08	FY09E	FY10E	FY11E
ROAE	61.3	62.8	54.1	49.6	44.8
ROACE	52.9	66.2	61.2	53.1	48.1
Debtor days	19	24	23	21	21
Inventory days	88	93	90	86	86
Payable days	167	196	204	175	164
Current ratio	1.4	1.1	1.1	1.3	1.5
Debt/EBITDA	0.5	0.2	0.2	0.2	0.2
Cash conversion cycle days	(59)	(79)	(91)	(69)	(57)
Debt/Equity	0.3	0.2	0.1	0.1	0.1
Adjusted debt/equity	0.3	0.2	0.1	0.1	0.1
Interest coverage (x)	20.6	21.9	26.3	28.7	38.2

Operating ratios

Year to March	FY07	FY08	FY09E	FY10E	FY11E
Total asset turnover	3.2	3.4	3.3	3.2	2.9
Fixed asset turnover	4.6	5.6	4.7	4.3	4.5
Equity turnover	4.2	4.3	3.8	3.6	3.2

Du pont analysis

Year to March	FY07	FY08	FY09E	FY10E	FY11E
NP margin (%)	13.9	14.2	13.8	13.7	13.8
Total assets turnover	3.2	3.4	3.3	3.2	2.9
Leverage multiplier	1.4	1.3	1.2	1.1	1.1
ROAE (%)	61.3	62.8	54.1	49.6	44.8

Valuation parameters


Year to March	FY07	FY08	FY09E	FY10E	FY11E
Diluted EPS (INR)	3.3	3.9	4.4	5.2	5.9
Y-o-Y growth (%)	24.5	18.1	12.9	18.6	14.1
CEPS (INR)	3.7	4.3	4.8	5.8	6.6
Diluted P/E (x)	28.8	24.4	21.6	18.2	16.0
Price/BV (x)	17.7	13.5	10.3	8.1	6.4
EV/Sales (x)	4.0	3.3	2.9	2.4	2.1
EV/EBITDA (x)	23.5	19.2	17.6	14.4	12.4
Dividend yield (%)	1.5	1.6	2.0	2.4	2.7

Naresh Kothari	Co-Head Institutional Equities	naresh.kothari@edelcap.com	+91 22 2286 4246
Vikas Khemani	Co-Head Institutional Equities	vikas.khemani@edelcap.com	+91 22 2286 4206
Nischal Maheshwari	Head Research	nischal.maheshwari@edelcap.com	+91 22 6623 3411

Coverage group(s) of stocks by primary analyst(s): FMCG

Asian Paints, Colgate, Dabur, Godrej Consumer, Hindustan Lever, ITC, Marico and Nestle

Dabur India



Recent Research

Date	Company	Title	Price (INR)	Recons
09-Mar-09	Nestle	Gross margin delights; Result Update	1,431	Accum.
03-Mar-09	Hindustan Unilever	Building its defences; Visit Note	242	Accum.
27-Feb-09	Asian Paints	Slow, but steady; Visit Note	786	Accum.
03-Feb-09	FMCG	Good days to continue; Sector Update		

Distribution of Ratings / Market Cap

Edelweiss Research Coverage Universe

	Buy	Accumulate	Reduce	Sell	Total
Rating Distribution*	74	63	30	10	182

* 4 stocks under review / 1 rating withheld

	> 50bn	Between 10bn and 50 bn	< 10bn
Market Cap (INR)	68	46	68

Rating Interpretation

Rating	Expected to
Buy	appreciate more than 20% over a 12-month period
Accumulate	appreciate up to 20% over a 12-month period
Reduce	depreciate up to 10% over a 12-month period
Sell	depreciate more than 10% over a 12-month period

This document has been prepared by Edelweiss Securities Limited (Edelweiss). Edelweiss, its holding company and associate companies are a full service, integrated investment banking, portfolio management and brokerage group. Our research analysts and sales persons provide important input into our investment banking activities. This document does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable, but we do not represent that it is accurate or complete and it should not be relied on as such. Edelweiss or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors. We and our affiliates, group companies, officers, directors, and employees may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as advisor or lender/borrower to such company (ies) or have other potential conflict of interest with respect to any recommendation and related information and opinions. This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Edelweiss and affiliates/ group companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe, any such restrictions. The information given in this document is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Edelweiss reserves the right to make modifications and alterations to this statement as may be required from time to time. However, Edelweiss is under no obligation to update or keep the information current. Nevertheless, Edelweiss is committed to providing independent and transparent recommendation to its client and would be happy to provide any information in response to specific client queries. Neither Edelweiss nor any of its affiliates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Past performance is not necessarily a guide to future performance. The disclosures of interest statements incorporated in this document are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. Edelweiss Securities Limited generally prohibits its analysts, persons reporting to analysts and their family members from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. Analyst holding in the stock: no.

Copyright 2007 Edelweiss Research (Edelweiss Securities Ltd). All rights reserved

Edelweiss Research is also available on Bloomberg EDEL <GO>, Thomson First Call, Reuters and Factset.